In this episode, Global Trac Solution’s CEO, David Flores, sits down with Dr. Hyder A. Khoja to learn more about the work they’re doing at Transcendent Therapeutics Inc.
Similar Posts
Spotlight Roundup-Another Psychedelic Company Lists On The Nasdaq
June 9, 2021- This week’s Psychedelic Business News top stories…
Interview with Matt Zemon, Co-Founder, Psychable
In our conversation with Matt, we tackle a variety of extremely important and highly-relevant subject matters such as how technology can be utilized to enhance the community of psychedelic healing, conscious capitalism, corporate responsibility, and how companies like Psychable are willing to go out of their way to connect with investors who are motivated not only by profit, but a company’s ability to contribute to the greater good of humanity.
MindMed Taking On The $30 BILLION Pain Relief Industry? [MMED / MNMD Expanding with Project Angie ]
Project Angie: Can MindMed Disrupt the Pain Relief Industry? [MMED / MNMD Expanding Horizons]
Breaking NEWS: MindMed ( MNMD / MMED / MMQ ) launching a new flagship program called Angie to advance the development of psychedelics, including LSD and potentially penetrate the pain killer industry by treating pain conditions. MindMed is currently exploring two primary clinical indications for the treatment of pain:
MindMed will initiate a study of LSD in a severe pain indication. MMED is currently preparing a pre-IND briefing package for this Phase 2a Proof of Concept study. They plan to submit to the FDA in the second half of 2021.
( As a note, that means they could present this doc anywhere between July 1st and December 31st. So it is conceivable that this trial could start at the tail end of 2021, if this doc gets presented at the beginning of that period.)
The second indication that MindMed is evaluating is “the common, often debilitating, chronic pain syndrome”.
Link to the 1964 study testing the LSDs ability to treat pain in cancer patients, and it had dual surprising results
: file:///C:/Users/maria/Downloads/Study_of_Lysergic_Acid_Diethylamide_as_an.13.pdf
Link to the 2020 a study was published that had among its authors 2 prominent MindMed collaborators: Mattias Liechti and Kim Kuypers: https://journals.sagepub.com/doi/full…
Link to the 2017study: https://www.ncbi.nlm.nih.gov/pmc/arti…
Link to MindMed ( MMED / MNMD/ MMQ ) : https://mindmed.co/
Link to MindMed ‘ s Press Release on Project Angie : https://mindmed.co/news/press-release…
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifa…
https://benzinga.grsm.io/thepsychedel…
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MindMedStock #MNMD
Interview with Bright Minds Biosciences’ CEO Ian McDonald
In today’s episode of the Psychedelic Spotlight podcast, the Psychedelic…
MindMed (MMED) Cluster Headaches LSD Trials Update (and response to criticisms)
Hey guys! Here is an Update and response to our easily most controversial video “MindMed (MMED) Suicide Headaches trial VANISHES from Website ( What Happened?)”. We got a response from MindMed while also receiving some backlash from the MindMed investors community that will be addressed. Hope you guys find some value in this video. I appreciate you guys. LOOVE all comments and criticisms. Caio!
P.S. S/O to Magic Shrooms who also contributed by commenting that he “received a reply from MMED concerning about the cluster headaches trial. they said that there has been no changes in regard to their on-going trial using LSD for suicide headaches!”
Just to let you know, we temporarily (perhaps permanently?) have removed the first video, while we discuss how to move forward.
Subscribe to our channel to get the latest updates on Psychedelic Stocks. Follow the MMED stock and other companies like it.
Let us know in the comments what you think about the new way we edited our video? Do you like it more than how we edited them previously?
🎵 Music: www.bensound.com
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #mmed #mindmedstock #psychedelicstocks #mmedf
Psychedelic Spotlight Interview with Daniel Carcillo
In this episode of the Psychedelic Spotlight podcast, we catch…